Primary Ciliary Dyskinesia
3
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
VP
ReCode TherapeuticsCA - Menlo Park
4 programs2
RCT1100Phase 11 trial
RCT1100Phase 11 trial
Sano Genetics Testing KitN/A1 trial
SpirometryN/A1 trial
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Vertex PharmaceuticalsVX-371
ReCode TherapeuticsRCT1100
ReCode TherapeuticsRCT1100
ReCode TherapeuticsSano Genetics Testing Kit
ReCode TherapeuticsSpirometry
Clinical Trials (5)
Total enrollment: 339 patients across 5 trials
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
Start: Aug 2016Est. completion: Nov 2018123 patients
Phase 2Completed
A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD
Start: Sep 2024Est. completion: Aug 20257 patients
Phase 1Completed
Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
Start: Feb 2023Est. completion: Jan 20259 patients
Phase 1Completed
A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials
Start: Aug 2023Est. completion: Dec 2025150 patients
N/AActive Not Recruiting
A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
Start: Mar 2023Est. completion: Jun 202550 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space